NCT00338299View on ClinicalTrials.gov

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

April 30, 2004

Conditions
AnemiaChemotherapy
Interventions
DRUG

Epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00338299 - Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia | Biotech Hunter | Biotech Hunter